Tirofiban-induced coronary thrombolysis.

receptor antagonists during coronary angioplasty has become more widespread due to several trials demonstrating clinical benefit during and after the p r o c e d u r e . – 3 These agents act by blocking the GP IIb/IIIa receptor on the surface of the platelet. The GP IIb/IIIa receptor binds circulating adhesive macromolecules and cross-links with the receptors of surrounding platelets, resulting in platelet aggregation. Tirofiban (Aggrastat; Merck, Inc., West Point, Pennsylvania), a new non-peptide platelet GP IIb/IIIa receptor blocker, has demonstrated efficacy when used in the context of percutaneous coronary interventions (PCI) and acute coronary syndromes. , 5 L i k e other GP IIb/IIIa antagonists, tirofiban is primarily used to prevent vessel closure in the setting of PCI and unstable angina. We report a case in which tirofiban acted as a thrombolytic agent to achieve reperfusion following acute vessel closure.